Effects of eplerenone on blood pressure and echocardiographic and serum biochemical variables in five healthy dogs: a pilot study
Effects of eplerenone on blood pressure and echocardiographic and serum biochemical variables in five healthy dogs: a pilot study
复制标题
依普利农对五只健康狗的血压、超声心动图和血清生化变量的影响：一项初步研究
DOI：
10.1155/2020/5193856
复制
发表时间：
2020
影响因子：
3.1
通讯作者：
Hikasa Y
中科院分区：
文献类型：
--
作者：
Arita S; Arita N;Hikasa Y
依普利酮（EP）是一种醛固酮拮抗剂，据报道在非犬种中产生肾脏和心脏保护作用。然而，尚无关于EP对犬心血管影响的详细报告。本研究旨在确定EP对健康犬超声心动图参数、血压和生化变量的影响。将5只健康Beagle犬随机分为3个剂量组，每组重复使用，经口给予2.5、5或10 mg/kg BW EP，q24 h，持续4周。在EP给药前和EP给药后1、2和4周进行血清生化检查、血压和多普勒超声心动图测量。EP治疗以剂量依赖性方式降低平均血压，（但以剂量非依赖性方式）降低左心房/主动脉比、舒张早期二尖瓣血流、舒张早期二尖瓣血流/舒张晚期二尖瓣血流、舒张早期二尖瓣血流峰值速度/舒张早期二尖瓣环运动峰值速度、左心室和右心室Tei指数、每搏输出量、心输出量，和给药后1 - 4周的收缩中期心肌速度梯度。给予EP后舒张早期二尖瓣血流减速时间明显延长。血清生化变量未观察到显著变化。结果表明，EP可减少前负荷，从而减小左房大小。此外，理论上可能会发生左心室僵硬度的降低，但无法使用本研究设计进行测试。表明在本研究所用剂量范围内给予EP对健康犬是安全的。需要进一步的研究来探索安全性和有效性，以及寻求EP治疗客户拥有的心脏病犬的推荐剂量范围。
Eplerenone (EP), an aldosterone antagonist, is reported to produce renal and cardiac protective effects in noncanine species. However, there are no detailed reports available on cardiovascular effects of EP in dogs. This study aimed to determine effect of EP on echocardiographic parameters, blood pressures, and biochemical variables in healthy dogs. Five healthy Beagle dogs were randomly divided and repeatedly used in each of 3 dose groups, receiving 2.5, 5, or 10 mg/kg BW EP orally q24 h for 4 wks. Serum biochemical test, blood pressure, and Doppler echocardiography measurements were performed before EP administration and at 1, 2, and 4 weeks after EP administration. Treatment with EP reduced mean blood pressure in a dose‐dependent manner and significantly (but in a dose‐independent manner) decreased left atrium/aorta ratio, early diastolic transmitral flow, early diastolic transmitral flow/late diastolic transmitral flow, peak velocity of early diastolic transmitral flow/peak velocity of early diastolic mitral annular motion, left ventricle and right ventricle Tei indices, stroke volume, cardiac output, and mid systole myocardial velocity gradient 1 to 4 weeks after administration. Deceleration time of early diastolic transmitral flow significantly increased after EP administration. No significant changes were observed in serum biochemical variables. The results indicated that EP might reduce preload, thereby decreasing left atrial size. In addition, reduction of left ventricular stiffness may have theoretically taken place but this could not be tested using the present study design. It is suggested that EP administration within the dose range used in this study is safe for administration to healthy dogs. Further studies are needed to explore both safety and efficacy, as well as to seek a recommended dose range of EP treatment in client‐owned dogs with heart disease.